Business Description
Defence Therapeutics Inc
NAICS : 325410
SIC : 3741
ISIN : CA24463V1013
Total Employee Number:
5Description
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development. It operates only in Canada.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.89 | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-Equity | 0.29 | |||||
Debt-to-EBITDA | -0.28 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 32.4 | |||||
3-Year EPS without NRI Growth Rate | 29.1 | |||||
3-Year FCF Growth Rate | 26 | |||||
3-Year Book Growth Rate | -27.9 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.12 | |||||
9-Day RSI | 42.46 | |||||
14-Day RSI | 44.56 | |||||
3-1 Month Momentum % | -17.87 | |||||
6-1 Month Momentum % | -38.01 | |||||
12-1 Month Momentum % | -37.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.37 | |||||
Quick Ratio | 3.37 | |||||
Cash Ratio | 3.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.3 | |||||
Shareholder Yield % | -0.77 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -2308.1 | |||||
ROA % | -171.53 | |||||
ROIC % | -229.61 | |||||
3-Year ROIIC % | 2580.25 | |||||
ROC (Joel Greenblatt) % | -3129.63 | |||||
ROCE % | -328.08 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 8.63 | |||||
Price-to-Tangible-Book | 8.63 | |||||
EV-to-EBIT | -6 | |||||
EV-to-EBITDA | -6.06 | |||||
EV-to-FCF | -7.59 | |||||
Earnings Yield (Greenblatt) % | -16.67 | |||||
FCF Yield % | -12.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:DTCFF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Defence Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.065 | ||
| Beta | 0.4661 | ||
| 3-Year Sharpe Ratio | -0.47 | ||
| 3-Year Sortino Ratio | -0.76 | ||
| Volatility % | 42.18 | ||
| 14-Day RSI | 44.56 | ||
| 14-Day ATR ($) | 0.046405 | ||
| 20-Day SMA ($) | 0.379312 | ||
| 12-1 Month Momentum % | -37.48 | ||
| 52-Week Range ($) | 0.3066 - 0.7787 | ||
| Shares Outstanding (Mil) | 75.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Defence Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Defence Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Defence Therapeutics Inc Frequently Asked Questions
What is Defence Therapeutics Inc(DTCFF)'s stock price today?
The current price of DTCFF is $0.35. The 52 week high of DTCFF is $0.78 and 52 week low is $0.31.
When is next earnings date of Defence Therapeutics Inc(DTCFF)?
The next earnings date of Defence Therapeutics Inc(DTCFF) is .
Does Defence Therapeutics Inc(DTCFF) pay dividends? If so, how much?
Defence Therapeutics Inc(DTCFF) does not pay dividend.
Guru Commentaries on OTCPK:DTCFF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Defence Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers